1-([1,1'-biphenyl]-4-ylmethyl)-2-Boc-hydrazine | 162739-87-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-([1,1'-biphenyl]-4-ylmethyl)-2-Boc-hydrazine
• 英文别名: N'-biphenyl-4-ylmethyl-hydrazinecarboxylic acid t-butyl ester；N'-biphenyl-4-ylmethylhydrazinecarboxylic acid t-butyl ester；N1-(tert-butoxycarbonyl)-N2-(4-biphenylylmethyl)hydrazine；tert-butyl N-[(4-phenylphenyl)methylamino]carbamate
• CAS: 162739-87-9
• 化学式: C₁₈H₂₂N₂O₂
• 分子量: 298.385
• InChiKey: FNMVTGLKOYJBBF-UHFFFAOYSA-N

物化性质

• 熔点：
  84-85 °C
• 密度：
  1.086±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-([1,1'-biphenyl]-4-ylmethyl)-2-Boc-hydrazine 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 0.5h， 生成 3-[[[(2R)-2-hydroxy-3-methoxy-3-oxopropyl]-[(4-phenylphenyl)methyl]amino]carbamoyl]-1H-pyrazole-5-carboxylic acid
  参考文献：
  名称：

  NEPRILYSIN INHIBITORS

  摘要：

  在一方面，本发明涉及具有以下公式的化合物： 其中R1-R6、a、b和X如说明书所述，或其药用可接受的盐。这些化合物具有中性粒细胞弹性蛋白酶抑制活性。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。

  公开号：

  US20120157386A1
• 作为产物：
  描述：

  对苯基苯甲醛 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 4.0h， 生成 1-([1,1'-biphenyl]-4-ylmethyl)-2-Boc-hydrazine
  参考文献：
  名称：

  New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors:  Candidates for Clinical Development

  摘要：

  On the basis of previously described X-ray studies of an enzyme/aza-dipeptide complex,(8) azadipeptide analogues carrying N-(bis-aryl-methyl) substituents on the (hydroxethyl)hydrazine moiety have been designed and synthesized as HIV-1 protease inhibitors. By using either equally (12) ororthogonally (13) protected dipeptide isosteres, symmetrically and asymmetrically acylated aza-dipeptides can be synthesized. This approach led to the discovery of very potent inhibitors with antiviral activities (ED50) in the subnanomolar range. Acylation of the (hydroxethyl)hydrazine dipeptide isostere with the L-tert-leucine derivative 29 increased the oral bioavailability significantly when compared to the corresponding L-valine or L-isoleucine derivatives. The bis(L-tert-leucine) derivatives CGP 75355, CGP 73547, CGP 75136, and CGP 75176 combine excellent antiviral activity with high blood concentration after oral administration. Furthermore, they show no cross-resistance with saquinavir-resistant strains and maintain activity against indinavir-resistant ones. Consequently they qualify for further profiling as potential clinical candidates.

  DOI：

  10.1021/jm970873c

文献信息

• NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS
  申请人：Mammen Mathai

  公开号：US20130323271A1

  公开（公告）日：2013-12-05

  In one aspect, the invention relates to compounds having the formula: where R 1 , R 2 , R 3 , R 7 , R 8 , Z, X, b, and c are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are nitric oxide donors and have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

  在一方面，本发明涉及具有以下公式的化合物：其中R1、R2、R3、R7、R8、Z、X、b和c按说明书定义，或其药用可接受的盐。这些化合物是氧化氮供体并具有中性内肽酶抑制活性。在另一方面，本发明涉及包含此类化合物的药物组合物；使用此类化合物的方法；以及制备此类化合物的过程和中间体。
• Synthesis and Properties of Hydrazino Amino Acyclic Carbenes of Gold(I), Platinum(II), Palladium(II) and Rhodium(III)
  作者：Svetlana Tšupova、Matthias Rudolph、Frank Rominger、A. Stephen K. Hashmi

  DOI：10.1002/adsc.201600615

  日期：2016.12.22

  The nucleophilic addition of protected and substituted hydrazine derivatives to isonitrile complexes of gold(I), platinum(II), palladium(II) and rhodium(III) provides the corresponding hydrazino amino acyclic carbene complexes. These are characterized by their spectroscopic data, four different X‐ray single crystal structure analyses and their catalytic activity in the gold(I)‐catalyzed cycloisomerization

  将受保护和取代的肼衍生物亲核加成到金（I），铂（II），钯（II）和铑（III）的异腈配合物中，提供了相应的肼基氨基无环卡宾配合物。它们的特征在于其光谱数据，四种不同的X射线单晶结构分析及其在金（I）催化的N-炔丙基甲酰胺向亚烷基新恶唑啉的环异构化中的催化活性。
• Methods of treating alzheimer's disease
  申请人：Schostarez Heinrich

  公开号：US20050130941A1

  公开（公告）日：2005-06-16

  Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of hydrazine compounds of formula (I) wherein the variables R 1 -R 9 are defined herein.

  本发明涉及使用式(I)中变量R1-R9所定义的肼化合物治疗阿尔茨海默病和其他疾病，抑制β-分泌酶酶活性，抑制A beta肽在哺乳动物体内的沉积。
• Antiretroviral hydrazine derivatives
  申请人：Novartis Corporation

  公开号：US05753652A1

  公开（公告）日：1998-05-19

  The invention relates to compounds of formula ##STR1## and salts, pharmaceutical compositions, intermediates and processes of preparation thereof.

  本发明涉及式子##STR1##的化合物及其盐、药物组合物、中间体和制备方法。
• Neprilysin inhibitors
  申请人：Smith Cameron

  公开号：US08563512B2

  公开（公告）日：2013-10-22

  In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

  在一个方面，本发明涉及具有以下式子的化合物：其中R1-R6，a，b和X如规范中所定义，或其药学上可接受的盐。这些化合物具有抑制酶解酶的活性。在另一个方面，本发明涉及包含这些化合物的制药组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。